FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer

Table 2 Summary of the efficacy results

	Irinotecan-naïve, n = 30			Prior irinotecan, n = 35
Response rate
	n	%	%	n	%	%
		(ITT)	(evaluable)		(ITT)	(evaluable)
CR	0	0	0	1	2.8	2.9
PR	13	43.3	50	11	31.4	32.4
SD	10	33.3	38.5	9	25.7	26.5
PD	3	10	11.5	13	37.1	38.2
NE	4	13.3	-	1	2.8	-
ORR	13	43.3	50	12	34.3	35.3
DCR	23	76.7	88.5	21	60	61.8
Survivals
	median, mo	95%CI		median, mo	95%CI
PFS	11.3	6.1-29.0		5.7	3.9-10.4
OS	17.0	13.0-17.3		14.3	12.8-19.5

RR: Response rate; ITT: Intention-to-treat; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; NE: Not evaluable; ORR: Objective response rate; DCR: Disease control rate; PFS: Progression-free survival; OS: Overall survival.